Medovir (Aciclovir)

Aciclovir is a nucleoside analogue that is taken up by infected cells and phosphorylated to its active triphosphate form. This active metabolite competitively inhibits viral DNA polymerase, halting viral DNA synthesis and preventing replication of herpes simplex and varicella‑zoster viruses.

The dosage and frequency of Medovir are determined by the prescribing healthcare professional based on the specific indication, severity of the outbreak, patient age, and renal function. Patients should follow the prescriber’s instructions and the product label precisely.

Safety data for topical aciclovir in pregnancy and lactation are limited. Healthcare providers usually weigh the potential benefits against any theoretical risks. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their physician before starting treatment.

To order Medovir, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Medovir (aciclovir) and other topical antivirals such as penciclovir have similar mechanisms of inhibiting viral DNA synthesis. Aciclovir is well‑studied, widely available, and generally effective when applied early. Some clinicians prefer penciclovir for its longer intracellular half‑life, but clinical outcomes are comparable for most herpes lesions.

Medovir should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and avoid freezing. Follow any additional handling instructions provided on the label to maintain product stability.

Medovir is applied directly to the affected skin area. The prescribed amount is spread in a thin layer using clean hands, typically five times daily for the first few days of an outbreak, then reduced as directed by the prescriber. Hands should be washed before and after application.

Serious risks, although rare, include severe allergic reactions such as Stevens‑Johnson syndrome, anaphylaxis, and ocular irritation if the product contacts the eye. Systemic absorption can lead to renal toxicity, especially in patients with pre‑existing kidney impairment. Immediate medical attention is required if any severe reaction occurs.

Medovir should be avoided in individuals with known hypersensitivity to aciclovir or any of the excipients, in patients with severe renal impairment unless dose‑adjusted by a physician, and in anyone with extensive broken skin or open wounds at the intended application site.